MTNB - Matinas BioPharma Holdings Inc Stock Price, Fair Value and News

$0.76-0.05 (-6.17%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

MTNB Price Action

Last 7 days

4.1%

Last 30 days

-43.3%

Last 90 days

-55.0%

Trailing 12 Months

38.2%

MTNB RSI Chart

MTNB Valuation

Market Cap

4.9M

Price/Earnings (Trailing)

-0.29

Price/Sales (Trailing)

6.84

EV/EBITDA

-0.09

Price/Free Cashflow

-0.54

MTNB Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

MTNB Fundamentals

MTNB Revenue

Revenue (TTM)

1.1M

MTNB Earnings

Earnings (TTM)

-16.9M

Earnings Growth (Yr)

64.16%

Earnings Growth (Qtr)

70.79%

MTNB Profitability

EBT Margin

-2219.98%

Return on Equity

-261.08%

Return on Assets

-173.97%

Free Cashflow Yield

-185.1%

MTNB Investor Care

Shares Dilution (1Y)

25.93%

Diluted EPS (TTM)

-3.42

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	4.3M	3.2M	2.2M	1.1M
2022	0	2.3M	2.7M	3.2M
2021	462.7K	916.9K	1.4M	1.8M
2020	0	0	185.6K	8.5K
2019	0	179.6K	89.8K	89.8K
2018	164.7K	209.6K	164.7K	119.8K
2017	151.8K	119.7K	104.8K	149.7K
2015	0	0	0	194.5K

Get all data in R, Python etc through our Historical Stock Data APIs

About Matinas BioPharma Holdings Inc

Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. It develops products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nano-crystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is LYPDISO, a prescription-only omega-3 fatty acid-based composition intended for the treatment of cardiovascular and metabolic conditions. The company also offers MAT2203, an oral formulation of amphotericin B that is in Phase II clinical trials for the prevention of invasive fungal infections due to immunosuppressive therapy in patients. In addition, it provides MAT2501, an orally administered formulation of the broad-spectrum aminoglycoside antibiotic amikacin that has completed Phase I clinical trials to treat various types of multidrug-resistant bacteria, including non-tuberculous mycobacterium infections, as well as various multidrug-resistant gram negative and intracellular bacterial infections. Matinas BioPharma Holdings, Inc. has a research collaboration with the National Institute of Allergy and Infectious Diseases for the development of Gilead's antiviral remdesivir; and a feasibility collaboration with Genentech, Inc. for the development of oral formulations. Matinas BioPharma Holdings, Inc. was incorporated in 2013 and is based in Bedminster, New Jersey.

CEO	Mr. Jerome D. Jabbour J.D.
WEBSITE	matinasbiopharma.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	34

Matinas BioPharma Holdings Inc Frequently Asked Questions

What is the ticker symbol for Matinas BioPharma Holdings Inc? What does MTNB stand for in stocks?

MTNB is the stock ticker symbol of Matinas BioPharma Holdings Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Matinas BioPharma Holdings Inc (MTNB)?

As of Wed Dec 03 2025, market cap of Matinas BioPharma Holdings Inc is 4.87 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of MTNB stock?

You can check MTNB's fair value in chart for subscribers.

Is Matinas BioPharma Holdings Inc a good stock to buy?

The fair value guage provides a quick view whether MTNB is over valued or under valued. Whether Matinas BioPharma Holdings Inc is cheap or expensive depends on the assumptions which impact Matinas BioPharma Holdings Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for MTNB.

What is Matinas BioPharma Holdings Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Dec 03 2025, MTNB's PE ratio (Price to Earnings) is -0.29 and Price to Sales (PS) ratio is 6.84. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. MTNB PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Matinas BioPharma Holdings Inc's stock?

In the past 10 years, Matinas BioPharma Holdings Inc has provided -0.329 (multiply by 100 for percentage) rate of return.